Autres langues Kintor Pharmaceutical Limited

Actions

9939

KYG5273B1077

Recherche biotechnologique et médicale

Temps Différé Hong Kong S.E. 07:15:50 08/10/2026			Varia. 5j.	Varia. 1 janv.
1,650 ^HKD	-5,17%		-6,25%	-15,82%

21/09	Kintor Pharmaceutical Limited annonce la démission de Ming Ming Cheung de ses fonctions de secrétaire général conjoint, avec effet au 21 septembre 2026	CI
07/09	L'action Kintor Pharma progresse : un traitement dermatologique se rapproche de l'homologation après des résultats d'essais	MT

Autres langues

21/09	Kintor Pharmaceutical Limited Announces CFO Changes, Effective September 21, 2026
21/09	Kintor Pharmaceutical Limited Announces Resignation of Ming Ming Cheung as Joint Company Secretary with Effect from September 21, 2026
07/09	Kintor Pharma Shares Rise as Skin Tone Treatment Inches Closer to Approval After Trial Results
07/09	Kintor Pharmaceutical Limited Announces Successful Completion Of Long-Term Human Safety Trial Of KT-939
19/08	Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026
11/06	Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939
10/06	Kintor Pharmaceutical Limited Announces Positive Interim Result in Long-Term Human Safety Trial of Kt-939 and Commences Registration Application for New Raw Material
28/05	Kintor pharmaceutical says CEO via wholly owned co increases shareholding by 2.51 million shares
27/05	Kintor Pharmaceutical Auditor to Retire; Shares Drop 7%
26/05	Kintor Pharmaceutical Limited Announces Change of Address of Principal Place of Business in Hong Kong, with Effect from 1 June 2026
21/04	Kintor Pharmaceutical's 2026 Sales Jump Past 2025 Full-Year Level
20/04	Kintor Pharmaceutical says ytd 2026 sales revenue at RMB34 million
20/04	Kintor Pharmaceutical Limited Provides Sales Guidance for the Year 2026
20/04	Kintor Pharmaceutical Limited Announces Preliminary Sales Results for the Year to Date Ended April 20, 2026
30/03	Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025
19/03	Kintor Pharma's Androgenetic Alopecia Drug Meets Primary Endpoint in Phase 3 Trial; Shares Plunge 21%
18/03	Kintor pharmaceutical says pharma's KX-826 phase III trial in China reaches primary endpoint
18/03	Kintor Pharmaceutical Limited Announces Phase III Clinical Trial Results For KX-826 Tincture 1.0% For Male Adult AGA In China
18/03	Shanghai Chicmax Cosmetic Signs KT-939 Cooperation Deal With Kintor Unit
13/03	Kintor Pharma Signs Cosmetic Development Deal With Fonow Medicine
12/03	Kintor Pharmaceutical's unit enters into cooperation agreement with Zhejiang Fonuw Medicine
26/01	Kintor Pharmaceutical Chief Executive Boosts Holding
26/01	Kintor Pharmaceutical says chairman buys 4.7 mln co shares for HK$10.82 mln from Nov 17, 2025 to Jan 23
21/01	Koshine Hong Kong Limited Enters into an Exclusive Sales Agency Agreement with Beijing Dekai Pharmaceutical Technology Co., Ltd
21/01	Kintor Pharmaceutical enters exclusive sales agency agreement for anti-hair loss foam product